Cornucopian Capital的动态

??October 23, 2024, Modifi Biosciences, Inc. today announced that the company has been acquired by Merck.?The deal includes a preclinical asset called KL-50 - which is designed to take on the tough-to-treat brain cancer glioblastoma (GBM). Biosciences shareholders are also eligible to receive potential milestone payments totaling up to $1.3 billion. Genomeditech is a high-tech enterprise specializing in the research and development of cutting-edge biotechnology technologies founded in 2011. With twelve years of deep experience in the industry, we have created a technology platform with independent intellectual property rights in molecular biology, cell biology, viral packaging, cell line construction, reporter genes, antibody expression, protein expression, IVD and other technologies. Genomeditech can provide customers with thousands of stock carriers and one-stop customization services. ??learn more about us :https://lnkd.in/gPyAytK2 ?? [email protected] #News#antibodydiscovery #antibodytherapeutics #celllinedevelopment #cancertreatment #antibodies #drugdiscovery #breakthrough #bispecific antibody

Vevo Therapeutics, a biotechnology company using its Mosaic technology and next generation AI to uncover better drugs for more patients, announced today that it has generated the world's largest single-cell atlas of how drugs interact with and affect tumor cells. The company's Mosaic platform is the first to make pan-cancer testing of drugs at single-cell resolution scalable. Hani Goodarzi, Kevan Shokat, and Johnny Yu are the UCSF co-founders, and we at Innovation Ventures congratulate them all! More: https://lnkd.in/gr78jpHv #ucsf, #innovation, #ai

?? In Case You Missed It Last Week! We proudly announced our €1.3M seed investment, marking a significant milestone for Inside Therapeutics. This funding bolsters our mission to accelerate patient access to RNA therapeutics through our innovative nanomedicine formulation systems. For those who don't know us (yet), here's a snapshot: ? Inside Therapeutics, based in Bordeaux, we aim to become a major player in the bioproduction sector of nanomedicines in Europe and internationally (with a focus on the US market) ? We have developed a proprietary technology for encapsulating RNA in lipid nanoparticles. ? Our ultimate goal: to enable laboratories developping nanomedicine and RNA therapies to save time and reduce the risk of failure by simplifying the access to nanoparticle formulation and streamlining their development/scale-up process. ? Our mission: to simplify patient access to nanomedicines, ultimately improving treatment!" A big thank you again to our investors: Newfund, SKALEPARK, Marc Le Bozec Learn more: https://lnkd.in/eitrKmk7

Bicycle Therapeutics Plc ADR is a biotechnology company based in the United Kingdom that specializes in developing novel therapies using its proprietary bicyclic peptide technology, known as Bicycles?. These molecules combine the pharmacological properties of antibodies with the manufacturing and tissue-penetration advantages of small molecules, aiming to address unmet needs in oncology and other serious diseases. Today, the company's stock

Don't miss our webinar on Monday 30th September, my colleague Jin Lu will discuss the latest advancements in therapeutic protein expression. #Biologics #Lonza #LonzaInYourLab #Biotechnology

NanoVation Therapeutics?, a Vancouver, BC, Canada-based platform company developing technologies to overcome barriers to nucleic acid delivery, raised an undisclosed amount in funding. Convergent Ventures led the round. The company intends to use the funds to support the further advancement of its lipid nanoparticle (LNP) technology platform for RNA delivery to cells outside of the liver, including completing large animal studies. https://lnkd.in/gfAfCPJT

The Swiss Biotech Day event has just ended. I wanted to share some thoughts after very interesting conversations and talks. ??? It's simply amazing to see AI revolutionising the pharma and biotech industries, from drug development to clinical trial optimisation. ?? Biologics, such as ADCs, nanoparticles (such as exosomes and viral vectors) and cell therapies are sparking conversations for their role, especially in cancer treatments. The potential is thrilling! ?? Rejuvenation is marking a new frontier for therapeutic innovation. ?? The impact of Annex 1 is undeniable, leading to major restructuring for some CDMOs to stay ahead. ?? Start-up pitches? Pure dynamism and creativity! ?? Finally, witnessing the strategic investments flowing into Switzerland was a highlight. Multicultural, innovative, government support are the main drivers for investors to look into Swiss companies. #SwissBiotechDay #BiotechInnovation #InvestmentTrends #GlobalBiotech

Artiva Biotherapeutics, a clinical-stage NK cell therapy biotech, is trying again for the public markets, it revealed Friday afternoon in an #SEC filing. The San Diego biotech is going for a Nasdaq debut but in a very different biotech financing environment than when it originally sought an #IPO in the spring of 2021, at a time when large public floats were easier to achieve thanks to low interest rates and generalist investors’ intrigue in drug development. And this time around, it’s without partner Merck, which axed their CAR-NK solid tumor collaboration last October, according to Friday’s S-1 filing. #NKcelltherapy #celltherapy #cellandgenetherapy #advancedtherapies #publicmarkets #biotech #biotechnology #financing #funding #lifescience #lifesciences #IPOs #solidtumors #bloodcancers #autoimmunedisease GC Cell 5AM Ventures venBio RA Capital Management

We are thrilled to announce Madrona's investment and the official launch of Aizen Therapeutics. We invested alongside our friends at Wilson Hill Ventures and Cercano to form the initial investing syndicate. We were lucky to have met founder David Van Valen, M.D. Ph.D. and founding CEO Ajay Kshatriya early in their company-building journey and to partner with them from day one. Aizen is taking on the challenge of designing and developing Mirror Peptides with its novel drug discovery platform DaX - an AI-based platform for exploring, designing, and optimizing D-amino acid-based therapeutics. This platform emerged from research in Dr. Van Valen's lab at Caltech, which has long focused on developing leading AI approaches to challenging problems in biology. Aizen represents another true day one investment for Madrona and our first investment in a Caltech spinout. We are always excited to partner with incredible founding teams at the beginning of their journey and help them achieve their visions from the start. Read our blog by Partner Chris Picardo and Investor Joseph Horsman for more details about why we invested and why we are so excited about Aizen's vision and their cutting-edge approach to developing mirror peptides: https://lnkd.in/gHGTaKw2

Helicore Biopharma emerged from stealth with a $65M series A led by Versant Ventures, OrbiMed, Longitude Capital and Wellington Management. Key points: ?? The biotech is developing a differentiated pipeline of antibody GIP agonists for obesity and related conditions ?? HCR-188, a clinic-ready antibody, is entering FiH studies with top-line data anticipated in the second half of 2025 ?? Building on existing validation of GIP pathway antagonism with a differentiated antibody format and a novel focus on binding to GIP, rather than to GIP receptor Release: https://lnkd.in/gdxC8qA7